Study guide
14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing
Certified Burn Registered Nurse CBRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Foundations of Burn Care
1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones
2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response
2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology
3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria
3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics
4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)
4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy
5 Chapter 5: Airway Management & Inhalation Injury Management
5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)
6 Chapter 6: Acute Multisystem Assessment & Critical Care Management
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection
7 Chapter 7: Hypermetabolism & Nutritional Support
7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation
8 Chapter 8: Pain Management in Burn Care
8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction
9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus
9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients
10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings
10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances
11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure
11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management
12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy
12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion
13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries
13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy
14 Chapter 14: Special Burn Populations & Cutaneous Syndromes
14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries
15 Chapter 15: Rehabilitation, Scar Management & Reconstruction
15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management
16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage
16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response
14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing
Key Takeaways Explain This Topic AI
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent life-threatening severe cutaneous adverse reactions (SCARs) driven by cytotoxic CD8+ T-cell and NK-cell release of granulysin, perforin/granzyme B, and Fas-FasL, inducing massive pan-epidermal keratinocyte apoptosis and pan-mucosal sloughing.
The disease continuum is classified strictly by the extent of Body Surface Area (BSA) exhibiting epidermal detachment: SJS (<10% TBSA with ≥2 mucosal sites), SJS/TEN Overlap (10% to 30% TBSA), and TEN / Lyell's Syndrome (>30% TBSA detachment).
The SCORTEN prognostic scoring system evaluates 7 independent clinical and laboratory parameters calculated within the first 24 hours of admission (Age ≥40, HR ≥120, Malignancy, BSA detachment ≥10%, BUN >28 mg/dL, Glucose >252 mg/dL, Bicarbonate <20 mEq/L); a SCORTEN ≥5 predicts ~90% in-hospital mortality.
Wound care in SJS/TEN strictly CONTRAINDICATES surgical debridement or tangential excision because the underlying dermis is vital and intact; nursing management mandates leaving detached epidermis in situ as a biological dressing roof, gentle non-shear wound cleansing, and applying non-adherent silicone or biosynthetic barriers.
Immediate cessation of all suspect/culprit medications and early transfer to an ABA-verified burn center cuts mortality in half, while intensive emergency ophthalmologic care (preservative-free lubrication, daily symblepharon lysis, and amniotic membrane grafting) is mandatory to prevent permanent blindness.
Last updated: August 2026
14.3 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing
Core Knowledge: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN, or Lyell's Syndrome) are acute, life-threatening severe cutaneous adverse reactions (SCARs) characterized by extensive keratinocyte apoptosis, widespread epidermal necrolysis, and severe multi-mucosal sloughing. Although not caused by thermal energy, SJS and TEN produce systemic pathophysiological sequelae identical to major partial-thickness thermal burns—including massive evaporative fluid loss, electrolyte derangements, catastrophic barrier failure, hypermetabolism, and sepsis. Specialized burn center admission, conservative non-surgical wound preservation, meticulous multi-mucosal care (especially ocular preservation), and prompt drug discontinuation are essential to patient survival.
1. Pathophysiology and Immunobiology of SJS / TEN
SJS and TEN represent a disease continuum triggered predominantly by a delayed, cell-mediated (Type IVc) hypersensitivity reaction to specific medications. IMMUNOPATHOLOGICAL CASCADE IN SJS / TEN
- ┌────────────────────────────────────────────────────────────────────────┐
- │ 1. DRUG-MHC CLASS I PRESENTATION & T-CELL ACTIVATION │
- │ • Culprit drug metabolite binds to Human Leukocyte Antigen (HLA-I). │
- │ • Clonally expanded cytotoxic CD8+ T-lymphocytes & Natural Killer cells│
- │ infiltrate the dermo-epidermal junction. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 2. MASSIVE RELEASE OF CYTOTOXIC MEDIATORS │
- │ • GRANULYSIN (Primary Mediator): 15-kDa cytolytic pore-forming protein │
- │ secreted in blister fluid; directly triggers widespread keratinocyte │
- │ necroptosis and apoptosis. Levels correlate with disease severity. │
- │ • Perforin & Granzyme B: Cleave caspase cascades within target cells. │
- │ • Soluble Fas Ligand (sFasL): Binds Fas receptor (CD95) on basal │
- │ keratinocytes, initiating death-receptor-mediated apoptosis. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 3. HISTOPATHOLOGICAL SEPARATION: Full-thickness epidermal necrosis │
- │ with subepidermal split at the dermo-epidermal basement membrane; │
- │ the underlying DERMIS REMAINS VIABLE AND INTACT. │
- └────────────────────────────────────────────────────────────────────────┘
Differentiation from Staphylococcal Scalded Skin Syndrome (SSSS):
In SJS/TEN , apoptosis occurs across the entire full-thickness epidermis, causing separation at the dermo-epidermal junction (subepidermal split) with mucosal involvement in > 90 % >90\% > 90% of cases.
In SSSS , Staphylococcus aureus exfoliative toxins A and B cleave desmoglein-1, producing a superficial intraepidermal split at the stratum granulosum ; mucous membranes are spared, and mortality is low ( < 5 % <5\% < 5% in children).
2. High-Risk Causative Medications and Genetic Susceptibility
Over 85% of TEN cases and 70% of SJS cases are drug-induced. Symptoms typically manifest 1 to 3 weeks (7 to 21 days) following initial drug exposure (or within hours upon re-exposure). HIGH-RISK CULPRIT MEDICATIONS MATRIX
- ┌─────────────────────────┬─────────────────────────┬─────────────────────────┐
- │ Medication Class │ Specific Common Agents │ High-Risk Allele / Notes│
- ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
- │ Anti-Gout / Xanthine │ Allopurinol │ HLA-B*58:01 │
- │ Oxidase Inhibitors │ │ (Highest global cause) │
- ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
- │ Aromatic Antiepileptics │ Carbamazepine, Phenytoin│ HLA-B*15:02 (Asian) │
- │ │ Lamotrigine, Phenobarb. │ HLA-A*31:01 (European) │
- ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
- │ Sulfonamide Antibiotics │ Trimethoprim- │ Common in both adults │
- │ │ sulfamethoxazole (Bactrim)│ and pediatric cohorts │
- ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
- │ NSAIDs (Oxicam Class) │ Piroxicam, Meloxicam │ Highest risk among │
- │ │ │ all NSAID classes │
- ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
- │ Antiretrovirals (NNRTI) │ Nevirapine │ High incidence in HIV+ │
- ├─────────────────────────┼─────────────────────────┼─────────────────────────┤
- │ Other Antibiotics │ Cephalosporins, Quinol- │ Broad-spectrum exposure │
- │ │ ones, Aminopenicillins │ │
- └─────────────────────────┴─────────────────────────┴─────────────────────────┘
- 3. Disease Classification Spectrum and Clinical Presentation
The disease spectrum is classified based on the percentage of total body surface area exhibiting actual or impending epidermal detachment : SJS / TEN SPECTRUM CLASSIFICATION
- ┌────────────────────────────────────────────────────────────────────────┐
- │ STEVENS-JOHNSON SYNDROME (SJS) │
- │ • Epidermal Detachment: < 10% TBSA │
- │ • Multi-mucosal involvement (≥ 2 anatomical sites) in > 90% of cases │
- │ • Expected Mortality: 1% – 5% │
- ├────────────────────────────────────────────────────────────────────────┤
- │ SJS / TEN OVERLAP SYNDROME │
- │ • Epidermal Detachment: 10% to 30% TBSA │
- │ • Widespread atypical targetoid macules with confluent purpuric patches│
- │ • Expected Mortality: 10% – 15% │
- ├────────────────────────────────────────────────────────────────────────┤
- │ TOXIC EPIDERMAL NECROLYSIS (TEN / Lyell's Syndrome) │
- │ • Epidermal Detachment: > 30% TBSA (frequently > 50%–70% TBSA) │
- │ • Sheet-like epidermal sloughing, severe pan-mucosal ulceration │
- │ • Expected Mortality: 25% – 50% (up to 90% with high SCORTEN) │
- └────────────────────────────────────────────────────────────────────────┘
Clinical Phases and Hallmark Physical Signs:
Prodromal Phase (1 to 3 Days Prior to Rash): High-grade fever ( > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C ), malaise, severe sore throat, stinging/photophobia of the eyes, arthralgias, and dysphagia.
Exanthematous Phase: Symmetrical eruption of tender, dusky erythematous macules or flat, atypical 'targetoid' lesions (2 concentric rings, unlike typical 3-ring erythema multiforme) starting on the face and trunk before spreading to extremities.
Necrotic / Bullous Phase: Lesions coalesce into large, flaccid bullae containing clear or serosanguinous fluid.
Hallmark Physical Examination Signs:
Positive Nikolsky Sign: Gentle lateral mechanical sliding pressure applied with a finger on normal-appearing perilesional or erythematous skin produces dislodgement and peeling of the epidermis from the dermis.
Positive Asboe-Hansen Sign (Bullous Spread Sign): Vertical pressure applied to the center of an intact flaccid blister forces fluid to dissect laterally under adjacent uninjured epidermis.
Multi-Mucosal Involvement ( ≥ 2 \ge 2 ≥ 2 Sites in > 90 % >90\% > 90% ):
Ocular: Severe conjunctival injection, chemosis, pseudomembrane formation, corneal erosions, and symblepharon.
Oral: Hemorrhagic crusting of vermilion borders, painful denudation of buccal mucosa, palate, and pharynx.
Urogenital: Erosive vaginitis, vulvar ulceration, urethritis, labial or foreskin synechiae.
Respiratory / GI: Tracheobronchial epithelial sloughing (requiring mechanical ventilation), severe esophageal erosions.
4. SCORTEN Prognostic Scoring System
SCORTEN is the internationally validated prognostic score developed by Bastuji-Garin et al. to predict in-hospital mortality in SJS and TEN. It comprises 7 independent clinical and laboratory variables , each scored as 1 point if present. SCORTEN must be calculated within the first 24 hours of admission , and ideally recalculated on Day 3 to capture disease progression. THE 7 SCORTEN VARIABLES MATRIX
- ┌───┬──────────────────────────────────┬─────────────────────────────────┐
- │ # │ SCORTEN Parameter │ Criterion Threshold (1 Pt Each) │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 1 │ Age │ ≥ 40 years │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 2 │ Heart Rate │ ≥ 120 beats/min │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 3 │ Associated Malignancy │ Present (Cancer / Hematologic) │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 4 │ Epidermal Detachment on Day 1 │ ≥ 10% TBSA │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 5 │ Serum Urea / BUN │ > 28 mg/dL (> 10 mmol/L) │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 6 │ Serum Glucose │ > 252 mg/dL (> 14 mmol/L) │
- ├───┼──────────────────────────────────┼─────────────────────────────────┤
- │ 7 │ Serum Bicarbonate (HCO3-) │ < 20 mEq/L (< 20 mmol/L) │
└───┴──────────────────────────────────┴─────────────────────────────────┘ SCORTEN MORTALITY CORRELATION BENCHMARK
- ┌─────────────────────┬───────────────────┬──────────────────────────────┐
- │ Total SCORTEN Score │ Predicted Mortality│ Clinical Acuity │
- ├─────────────────────┼───────────────────┼──────────────────────────────┤
- │ Score 0 – 1 │ 3.2% │ Low Risk │
- │ Score 2 │ 12.1% │ Moderate Risk │
- │ Score 3 │ 35.3% │ High Risk │
- │ Score 4 │ 58.3% │ Very High Risk │
- │ Score ≥ 5 │ 90.0% │ Critical / Extreme Mortality │
- └─────────────────────┴───────────────────┴──────────────────────────────┘
- 5. Specialized Burn Unit Nursing & Medical Management
Admission to an American Burn Association (ABA)-verified Burn Intensive Care Unit significantly reduces mortality in TEN compared to treatment on general medical or dermatology wards. TEN BURN UNIT NURSING & MEDICAL PROTOCOL
- ┌────────────────────────────────────────────────────────────────────────┐
- │ STEP 1: IMMEDIATE ELIMINATION OF THE CULPRIT DRUG │
- │ • Instantly discontinue all non-essential and suspect medications. │
- │ • Drugs with shorter elimination half-lives improve survival when │
- │ withdrawn early. Never re-challenge with cross-reactive classes. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ STEP 2: CONSERVATIVE NON-SURGICAL WOUND CARE (STRICT NO-EXCISION) │
- │ • SURGICAL EXCISION IS STRICTLY CONTRAINDICATED. The dermis is viable. │
- │ • Biological Roof Preservation: Leave detached, non-viable epidermis │
- │ in situ as a natural barrier to prevent fluid loss and infection. │
- │ • Gentle Irrigation: Sterile warm saline or 0.05% chlorhexidine. │
- │ • Non-Adherent Dressings: Apply soft silicone contact layers (Mepitel) │
- │ or biosynthetic temporary membranes (Biobrane, Suprathel, Allograft).│
- │ • AVOID Silver Sulfadiazine: Cross-reactive sulfa risk + leukopenia. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ STEP 3: EMERGENCY OPHTHALMOLOGICAL PRESERVATION │
- │ • Ophthalmology consult within 2 to 4 hours of BICU arrival. │
- │ • Preservative-Free Lubricants: Instill drops/ointments q 1–2 hours. │
- │ • Mechanical Symblepharon Lysis: Daily sweeping of fornices with a │
- │ sterile glass rod / muscle hook to prevent palpebral-bulbar adhesions│
- │ • Cryopreserved Amniotic Membrane Transplantation (AMT): Grafted over │
- │ palpebral conjunctiva & cornea within 48–72h to halt blinding fibrosis│
- ├────────────────────────────────────────────────────────────────────────┤
- │ STEP 4: UROGENITAL & ORAL MUCOSAL HYGIENE │
- │ • Oral: Viscous lidocaine, diphenhydramine, and chlorhexidine rinses. │
- │ • Urogenital: Lubricating petrolatum gauze to denuded vulva/penis; │
- │ soft vaginal molds/stents to prevent vaginal canal obliteration / │
- │ stenosis; indwelling catheter during active urethral sloughing. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ STEP 5: SYSTEMIC IMMUNOMODULATORY THERAPIES │
- │ • High-Dose IVIG (Intravenous Immunoglobulin, 2–3 g/kg total over 3–4d)│
- │ -> Blocks Fas-FasL-mediated keratinocyte apoptosis. │
- │ • Cyclosporine A (3–5 mg/kg/day IV/oral) -> Calcineurin inhibitor that │
- │ blocks CD8+ T-cell and NK-cell activation and halts granulysin. │
- │ • TNF-alpha Inhibitors (Etanercept 50 mg SC once) -> Rapid anti- │
- │ inflammatory effect; promotes accelerated re-epithelialization. │
- └────────────────────────────────────────────────────────────────────────┘
Critical Difference in Resuscitation Fluids:
Unlike thermal burns which destroy both epidermis and dermis and require massive crystalloid formulas ( 3 – 4 mL/kg/%TBSA 3\text{--}4\text{ mL/kg/\%TBSA} 3 – 4 mL/kg/%TBSA ), SJS/TEN fluid requirements are approximately two-thirds of thermal burn formulas (roughly 2.0 mL/kg/% epidermal detachment 2.0\text{ mL/kg/\% epidermal detachment} 2.0 mL/kg/% epidermal detachment ) because the underlying dermal vascular plexus remains partially intact. Fluid must be carefully titrated to maintain adult urine output at 0.5 mL/kg/hr while avoiding fluid creep and pulmonary edema.